Top 50 Biotechnology Startup Investors in Sweden in December 2024

Whether you are an investor or entrepreneur, partner with Sciety to achieve impactful returns and elevate your life science business in the Nordics.

We are a leading tech investor & venture builder in the Nordics. Taking deep tech from lab to market.WELCOMEINVESTMENTS

ALMI Invest is a venture capital company which invests in Swedish companies with exciting, scalable business models and motivated entrepreneurs. ALMI Invest consists of eight regionally based venture capital funds, all with local offices and experienced local investment managers. We manage a total of SEK 1 billion. Unlike most venture capitalists,we can invest in a wide range of businesses. A strong team of entrepreneurs, a scalable business model and an initial revenue stream are more important than the line of business when we invest.Our first, initial investment would typically be SEK 2-4 million. During the lifetime of an investment, sums of up to SEK 10 million can be ventured. We always syndicate with an investment partner (another venture capitalist or angel investor) from Sweden or otherwise which means that we can take a maximum of 50 percent of an investment round.ALMI Invest was founded in 2009 by ALMI Fretagspartner together with regional investors. Half of our capital comes from European Union structural funds, which accounts for an investment of SEK 500 million. The other 50 per cent comes from regional investors and ALMI Fretagspartner.

Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.

Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.

Welcome to Navigare Ventures. We invest in transformational early-stage companies at the frontier of science and technology.

We are a venture capital fund investigating in Start-Ups solving the worlds biggest problems while building massive businesses.

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

SEB Venture Capital is a Fintech investor that helps entrepreneurs and innovators launch and grow profitable businesses. They primarily serve as a strategic corporate venture focused on Fintech investments, with the option of partnering with SEB. They are also on the hunt for game-changing inventive solutions to new technologies that will make thefinancial industry smarter, safer, and more environmentally responsible, as well as more user-friendly. They also function as an evergreen fund, giving them the flexibility and staying strength to focus on long-term wealth development depending on what is best for the firm and its shareholders.

Crowberry Capital invests at seed and early stage in emerging technology ventures in the Nordics. Our mission is to back people that are good for companies and build companies that are good for people. We have a strong follow-through philosophy and commit to putting your company first.

Partnerinvest Norr is a private equity firm specialized in software, security, and biometrics sectors. Partnerinvest Övre Norrland AB is a venture capital firms that seeks to invest in limited companies which have are in the expansion phase.

Since 2005, Inventure has backed over 90 companies including Wolt, Swappie, Jobbatical, aiMotive, and more.

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Andreas is working on a service that will connect people, time and places on the web. He also works as an independent consultant helping other startups with product strategy, technical infrastructure, scalability and recruiting as well as financial companies (venture capital and private equity) with technical due diligence and in other advisorroles.He was CTO at Spotify from the launch of the company in August 2006 until November 2009. Before that he worked at Stardoll as an engineer and project manager.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

Noaber Ventures invests in initiatives that bring social transformations using information technology.

Hadean Ventures is a life science fund manager that invests in life science companies across europe with a particular focus on the nordic region. The funds are backed by leading private and institutional investors. Hadean Ventures has offices in oslo and stockholm and collaborates with world-class academic institutions and start-up hubs across theregion

Segulah Medical Acceleration is a Scandinavia-based investment company focusing on innovative medical technology companies in Europe.

EIR Ventures is a new Life Science Venture Group in the Nordics.

We help great minds unleash their full potential!

Voima Ventures’ mission is to solve major global problems by combining science, entrepreneurship, and value adding capital. They shed light on the ideas and technology which require time and courage to build. Industry domains include bio and new materials, medical technologies and life sciences, imaging and optics, IoT and electronics, robotics,software & ICT and AI. In addition, Voima Ventures has invested in more than 30 deep tech startups, including companies like Solar Foods, Infinited Fiber Company, and Dispelix. Cornerstone investors are VTT Technical Research Centre of Finland and European Investment Fund (EIF), backed by Finnish private and institutional investors.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

LIU invests in companies that are based on projects and ideas from Linköping University. LIU Invest is focused on investments in early phases. Investments are typically 250 000, but can be doubled by an additional investment.

On Sätila Holding, They are constantly looking for exciting new business ideas. They invest in start up, buy-out, expansion and reorganization. They go in as partners and their investments tend to be between 1 and 10 million.

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Beijer Ventures is an investment Firm.

Kale United offers a portfolio of over 75+ plant-based game changers

Landegren Gene Technology

I Love Lund is a venture capital firm.The firm seeks opportunities to invest in pre-seed rounds

SmiLe Inject Capital is an angel investment company to focus exclusively on early-stage life science companies.

PULS is specialized on DIN rail power supplies for industrial applications. We set standards in terms of efficiency, reliability, size and life time.

KTH Holding is a state-owned limited company managed by KTH's University Board. It invests in promising startup companies that are based on research or teaching at KTH, with the aim of supporting commercialization and making it easier for new science to benefit society.

Klimatet Invest is to create long-term value growth by investing relatively early in idea companies with good growth potential in cleantech and at the same time contributing to a more sustainable society.

Colibri Ventures invest in early-stage life science companies and help accelerate their innovations into commercial products.

Norrlandsfonden is a foundation that promotes the development of companies with growth ambitions. They offer flexible prime loans for new establishments, development, and expansion. They provide the opportunity for offensive and forward-looking investments and enable companies and people to grow.

Simon Fredriksson is the Co-Founder and CEO of Pixelgen Technologies. He attended Stanford University School of Medicine in 2003.

Hampus Jakobsson is a General Partner at early stage climate tech venture fund Pale Blue Dot.Prior to co-founding Pale Blue Dot, Hampus was a Venture Partner at science fund Blue Yard and a prolific angel investor with >100 angel investments. He co-founded of The Astonishing Tribe (acquired by Blackberry in 2010 for $150m). He left Blackberry2012 to found Brisk.io a sales productivity tool which folded 2016.

Ackra Invest AB is a venture capital and private equity firm specializing in late venture, growth capital and turnaround investments. The firm does not have a sector preference and seeks to invest in small and middle sized companies based in Norrland; the Northern region of Sweden. It does not provide loans or invest in seed or early venture. Thefirm takes minority stakes, between 10 percent and 49 percent and invests between SEK1 million ($0.13 million) and SEK8 million ($1.02 million). It invests in equity or convertible loans and can perform co-investments. The firm seeks to exit its investments within seven years. Ackra Invest AB was founded in 2005 and is based in Skellefteå, Sweden.

Teknoinvest is a premier Scandinavian venture capital company. They invest in areas of emerging technologies within the ITC and Life Sciences sectors. Their main geographical scope is Scandinavia and the USA. Teknoinvest was established as the first venture capital investment company. Teknoinvest is one of the most successful VC´s in Scandinaviaaccording to track record of value created for their investors.

ARCH Venture Partners provides seed / early stage venture capital for technology firms in information technology, life sciences, and physical sciences

Value creation for Healthcare & Life Sciences Ventures through capital, expertise, international network.

HJKK Didrikson operates as an investment firm.

Karolinska Institutet Holding is a subsidiary of KI Holding AB.

Life Science Invest is an investment firm that specializes in investment in the field of healthcare digital services and Medtech.

Phase2Phase Biopharma is a consulting company that offers CMC strategies, CRO, CMO, CDMO sourcing, CMC project management, and QA services.

JJDC, Inc. is the strategic venture capital arm of Johnson & Johnson Innovation. Learn more about our equity investment strategy.

We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food

A leader in the alternative asset space, TPG was built for a distinctive approach, managing assets through a principled focus on innovation.

TVM Capital Life Science is one of the transatlantic Venture Capital pioneers with teams based in North America and Europe.

Augmenta will invest in early stages of companies with unique products and strong growth potential.When portfolio companies have a fully developed product or service that is ready for commercialization, will Augmenta to leave their interests in portfolio companies. Exactly when this will happen will vary and depend on each company's uniquesituation.